肿瘤细胞治疗研究
英文原题：hiPSC-Derived M1 Macrophages Exhibit Synergistic Therapeutic Effects with Paclitaxel in Ovarian Cancer.
hiPSC-Derived M1 Macrophages Exhibit Synergistic Therapeutic Effects with Paclitaxel in Ovarian Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
卵巢癌仍然是最致命的妇科恶性肿瘤之一，对标准化疗的反应性有限，长期预后较差。肿瘤相关巨噬细胞，尤其是M2极化群体，在免疫抑制和肿瘤进展中发挥关键作用。人诱导多能干细胞（hiPSCs）可分化为功能性免疫细胞，为基于细胞的免疫治疗提供了无限且患者特异性的来源。在本研究中，我们探讨了hiPSC来源巨噬细胞（hiMACs），特别是M1极化hiMACs，对卵巢癌的治疗潜力。在共培养系统中，M1-hiMACs显著降低卵巢癌细胞的活力，诱导凋亡和坏死，而M0巨噬细胞效果甚微。在体内，向荷卵巢癌细胞的裸鼠静脉注射M1-hiMACs后，肿瘤体积呈剂量依赖性缩小。此外，与紫杉醇和M1-hiMACs联合治疗相比，单独使用任一治疗，联合治疗导致更大的肿瘤消退和增强的组织学坏死。这些发现证明了M1-hiMACs强大的抗肿瘤作用，并突出了其在卵巢癌细胞免疫治疗中的潜力，尤其是与化疗联合应用。
Ovarian cancer remains one of the most lethal gynecologic malignancies, with limited responsiveness to standard chemotherapy and poor long-term prognosis. Tumor-associated macrophages, particularly M2-polarized populations, play a crucial role in immune suppression and tumor progression. Human induced pluripotent stem cells (hiPSCs) can differentiate into functional immune cells, providing an unlimited and patient-specific source for cell-based immunotherapy.
In this study, we investigated the therapeutic potential of hiPSC-derived macrophages (hiMACs), specifically M1-polarized hiMACs, against ovarian cancer. In a co-culture system, M1-hiMACs significantly reduced the viability of ovarian cancer cells, inducing apoptosis and necrosis, whereas M0 macrophages showed minimal effects. In vivo , intravenous administration of M1-hiMACs into nude mice bearing ovarian cancer cells resulted in a dose-dependent reduction in tumor volume.
Furthermore, combination therapy with paclitaxel and M1-hiMACs led to greater tumor regression and enhanced histological necrosis compared to either treatment alone.
These findings demonstrate the potent anti-tumor effects of M1-hiMACs and highlight their potential for cellular immunotherapy for ovarian cancer, particularly in combination with chemotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
